Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

October 31, 2025

Conditions
Surgery
Interventions
DRUG

Sugammadex

Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.

OTHER

Placebo

Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.

Trial Locations (1)

60201

NorthShore University HealthSystem, Evanston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Endeavor Health

OTHER